CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG

Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM); company also appoints Chief Commercial Officer DEL MAR, Calif., June 24, 2026 /PRNewswire/ -- CeleCor Therapeutics has submitted the final section of its New Drug Application for the company's...